CommercialCoverageMedium impact
Policy Criteria Changes
Arkansas Blue Cross Blue Shield·AR · Oncology, Hematology·Medical Policy
Effective date
Jan 1, 2026
We identified it
Jun 19, 2026
Summary
Arkansas Blue Cross and Blue Shield has updated their preferred drug list for rituximab products used in cancer treatment. Riabni and Truxima are now preferred products, while Rituxan, Rituxan Hycela, and Ruxience are now non-preferred, which may require prior authorization or result in higher patient costs.
Action Required
Before January 1, 2026: Providers and billing team must update protocols to prioritize prescribing Riabni or Truxima over other rituximab products for oncology patients with Arkansas Blue Cross coverage. Update EMR drug formulary preferences and inform oncology providers of the preferred alternatives. Claims for non-preferred products may require prior authorization or face coverage limitations.